Randomized adaptive selection trial of cryotherapy, compression therapy, and placebo to prevent taxane-induced peripheral neuropathy in patients with breast cancer

[1] Windebank AJ(2008)Chemotherapy-induced neuropathy J Peripher Nerv Syst 13 27-46

[2] Grisold W(2008)Weekly paclitaxel in the adjuvant treatment of breast cancer N Engl J Med 358 1663-1671

[3] Sparano JA(2015)Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/Gynecologic Oncology Group study Gynecol Oncol 136 323-327

[4] Wang M(2020)Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209) J Clin Oncol 38 3841-3850

[5] Martino S(2011)Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy Breast Cancer Res Treat 125 767-774

[6] Jones V(2014)Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review Support Care Cancer 22 2261-2269

[7] Perez EA(2014)Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry Gynecol Oncol 135 510-517

[8] Saphner T(2020)Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO Guideline Update J Clin Oncol 38 3325-3348

[9] Wolff AC(2020)Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up Ann Oncol 31 1306-1319

[10] Sledge GW(2018)Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy: prospective self-controlled trial J Natl Cancer Inst 110 141-148

[1] Windebank AJ(2008)Chemotherapy-induced neuropathy J Peripher Nerv Syst 13 27-46

[2] Grisold W(2008)Weekly paclitaxel in the adjuvant treatment of breast cancer N Engl J Med 358 1663-1671

[3] Sparano JA(2015)Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/Gynecologic Oncology Group study Gynecol Oncol 136 323-327

[4] Wang M(2020)Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209) J Clin Oncol 38 3841-3850

[5] Martino S(2011)Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy Breast Cancer Res Treat 125 767-774

[6] Jones V(2014)Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review Support Care Cancer 22 2261-2269

[7] Perez EA(2014)Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry Gynecol Oncol 135 510-517

[8] Saphner T(2020)Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO Guideline Update J Clin Oncol 38 3325-3348

[9] Wolff AC(2020)Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up Ann Oncol 31 1306-1319

[10] Sledge GW(2018)Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy: prospective self-controlled trial J Natl Cancer Inst 110 141-148